[Non-small-cell lung cancer].
Molecular targeted therapy in combination with chemotherapy or thoracic radiotherapy has been studied in clinical trials. Gefitinib or erlotinib in combination with standard chemotherapy did not improve efficacy on survival over standard chemotherapy alone in chemotherapy-naive patients with advanced NSCLC. On the other hand, bevacizumab in combination with standard chemotherapy improved survival in chemotherapy-naive patients with advanced NSCLC, excluding squamous cell carcinoma. Multi-target tyrosine kinase inhibitors in combination with standard chemotherapy, and anti-EGFR antibodies and EGFR tyrosine kinase inhibitors in combination with thoracic radiotherapy, are under clinical trials.
Akita
Hirotoshi
H
Dept. of Medical Oncology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan.
Kinoshita
Ichiro
I
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000037:antagonists & inhibitors*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib